Session 133 - 12th CROI

Home

Session 133 Poster Abstracts
Pediatric Antiretroviral Therapy and Treatment Interruptions
Thursday, 1:30 - 3:30 pm
Hall B

764	Efficacy of Highly Active Antiviral Therapy and Rate of Genotypic HIV-1 Drug Resistant Strains among HIV-infected Children Receiving Treatment at the Agence Nationale de Recherche sur le SIDA, in Abidjan, Côte d'Ivoire, Africa Marie-Laure Chaix*¹, P Msellati^2,7, F Rouet³, K Kouakoussui⁴, M Anaky⁴, P Fassinou⁵, C Montcho³, S Blanche⁶, and C Rouzioux¹ ¹Univ Rene Descartes, Ctr Hosp Univ Necker, Paris, France; ²PACCI, Abidjan, Côte d'Ivoire; ³CeDReS/PACCI, Abidjan, Côte d'Ivoire; ⁴PACCI, Abidjan, Côte d'Ivoire; ⁵Ctr Hosp Univ Yopougon, Abidjan, Cote d'Ivoire; ⁶Ctr Hosp Univ Necker, Paris, France; and ⁷IRD-UR036, Montpellier, France
765	24-Week Safety and Efficacy of Enfuvirtide as Part of an Optimized ART Regimen in Children Andrew Wiznia*¹, J Church², P Emmanuel³, S Eppes⁴, L Rowell⁵, C Evans⁵, A Bertasso⁶, and the T20-310 Study Group ¹Jacobi Med Ctr, Bronx, NY, USA; ²Children’s Hosp of Los Angeles, CA, USA; ³All Children's Hosp, St Petersburg, FL, USA; ⁴Alfred I duPont Hosp for Children, Wilmington, DE, USA; ⁵Roche, Welwyn, UK; and ⁶Roche, Nutley, NJ, USA
766	A Prospective Evaluation of Pharmacologic, Virologic, and Immunologic Parameters of Lopinavir/Ritonavir for HIV-1-infected Infants < 6 Months of Age Ellen G Chadwick*¹, J Rodman², P Palumbo³, D Persaud⁴, J Chen⁵, J Gardella⁶, K Luzuriaga⁷, R Yogev¹, P Emmanuel⁸, M Rathore⁹, and PACTG 1030 Study Team ¹Northwestern Univ, Feinberg Sch of Med, Chicago, IL, USA; ²St Jude Children's Res Hosp, Memphis, TN, USA; ³Univ of Med and Dentistry of New Jersey, Newark, USA; ⁴Johns Hopkins Univ Sch of Med, Baltimore, MD, USA; ⁵Statistical and Data Analysis Ctr, Harvard Sch of Publ Hlth, Boston, MA, USA; ⁶PACTG Operations Office, Silver Spring, MD, USA; ⁷Univ of Massachusetts Med Sch, Worcester, USA; ⁸Univ of South Florida, Tampa, USA; and ⁹Univ of Florida, Jacksonville, USA
767	Pharmacokinetics of Atazanavir/Ritonavir in HIV-infected Infants, Children, and Adolescents: PACTG 1020A Jennifer Kiser*¹, R Rutstein², G Aldrovandi³, P Samson⁴, B Graham⁵, S Schnittman⁶, M Smith⁷, L Mofenson⁷, C Fletcher¹, and PACTG 1020 Study Team ¹Univ of Colorado Hlth Sci Ctr, Denver, USA; ²Children's Hosp of Philadelphia, PA, USA; ³Children’s Hosp of Los Angeles, CA, USA; ⁴Harvard Sch of Publ Hlth, Boston, MA, USA; ⁵Frontier Sci & Tech Res Fndn, Amherst, NY, USA; ⁶Bristol-Myers Squibb, Wallingford, CT, USA; and ⁷NIH, DHHS, Bethesda, MD, USA
768	Pharmacokinetics and 24-Week Efficacy and Safety of Saquinavir/Lopinavir/Ritonavir in RTI-pre-treated Children Jintanat Ananworanich*¹, P Kosalaraksa², U Siangphoe¹, A Hill³, A Bergshoeff⁴, C Pancharoen⁵, C Engchanil², J Sankote¹, J Intasan¹, A Chuamchaitrakool¹, D Cooper^6,7, P Phanuphak^5,7, K Ruxrungtham^5,7, and D Burger⁴ ¹HIV-NAT, Bangkok, Thailand; ²Khon Kaen Univ, Thailand; ³Univ of Liverpool, UK; ⁴Univ of Nijmegen, The Netherlands; ⁵Chulalongkorn Univ, Bangkok, Thailand; ⁶Natl Ctr in HIV Epidemiology and Clin Res, Univ of New South Wales, Sydney, Australia; and ⁷HIV-NAT, Bangkok, Thailand
769	6-Month Follow-up of Once-daily Lopinavir/ritonavir in HIV-1-infected Children Gwenda Verweel*¹, M van der Lee², D Burger², and R de Groot¹ ¹Erasmus Med Ctr, Sophia Children's Hosp, Rotterdam, The Netherlands and ²Univ Med Ctr Nijmegen, The Netherlands
770	Switching Stavudine to Tenofovir and Protease Inhibitor to Efavirenzr Results in a Favorable Clinical Outcome in HIV-infected Children Alessandra Viganò*¹, V Giacomet¹, S Beretta¹, M Merlo¹, C Figini¹, and S Mora² ¹Hosp Luigi Sacco, Milan, Italy and ²IRCCS Hosp San Raffaele, Milan, Italy
771	Clinical and Laboratory Consequences of Unplanned Treatment Interruptions in Perinatally HIV-infected Children and Adolescents S Heffernan-Vacca*, M Foca, B Na, A Jurgrau, and P LaRussa Columbia Univ, New York, NY, USA
772	Immunologic and Virologic Response after Unstructured Treatment Interruption in HIV-1-infected Children and Adolescents Akihiko Saitoh*, R Viani, and S Spector Univ of California, San Diego, USA
773	Outcomes of Treatment Interruption in HIV-infected Children Ariane Alimenti*, D Burdge, D Khoo, S Tatum, and J Forbes Children's and Women's Hlth Ctr of British Columbia, Univ of British Columbia, Vancouver, Canada